No Data
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 27% Share Price Plunge Could Signal Some Risk
Shandong Sinobioway Biomedicine (002581.SZ): plans to increase the capital of its wholly-owned subsidiary ShanDong YanDu by 0.29 billion yuan.
On January 3, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced the company is using its own funds to increase capital by 0.29 billion yuan for its wholly-owned subsidiary ShanDong Yandu Biotechnology Co., Ltd. (referred to as "ShanDong Yandu"), of which 0.29 billion yuan will be included in registered capital and 0 yuan in capital surplus. After the capital increase, ShanDong Yandu's registered capital will reach 0.3 billion yuan, remaining a wholly-owned subsidiary of the company. Meanwhile, the Board of Directors has authorized the company's management to handle the specific procedures related to the capital increase.
Shandong Sinobioway Biomedicine (002581.SZ) subsidiary plans to hire Happy Life to provide clinical trial technical services.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's Board of Directors has reviewed and approved the "Agreement on Signing the Technical..."
Shandong Sinobioway Biomedicine (002581.SZ): Granted 19.6346 million stock Options to 100 incentive targets.
On December 23, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced that the granting conditions stipulated in the "2024 Stock Options Incentive Plan (Draft) of Shandong Sinobioway Biomedicine Co., Ltd." have been met. According to the authorization of the fourth extraordinary Shareholders' Meeting of Shandong Sinobioway Biomedicine Co., Ltd. in 2024, the company held the 31st meeting of the 5th Board of Directors and the 21st meeting of the 5th Board of Supervisors on December 20, 2024, to review and approve the "Proposal on Granting Stock Options to the Incentive Objectives of the Company's 2024 Stock Options Incentive Plan," agreeing to use December 2024.
Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years
Shandong Sinobioway Biomedicine (002581.SZ) has appointed Zhou Ting as the financial director.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's board of directors recently received a report from the Chief Financial Officer, Mr. Liu Yangjun...
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
No Data
